MSME (Udyam registered) Ministry of MSME
- Category
- Small (2024-25)
- Udyam number
- UDYAM-GJ-06-0000911
Market Cap
₹14.26 Cr
NORRIS · BSE
Share Price
₹14.16
-0.70% today
Revenue
₹8.13 Cr
FY 2025-26 · +39.7% YoY
EBITDA
₹0.66 Cr
Margin 8.1%
Net Profit
−₹0.28 Cr
FY 2025-26 · +77.4% YoY
Authorised capital
₹10.1 Cr
Registered with MCA
Paid-up capital
₹9.93 Cr
Issued & subscribed
Open charges
₹3.57 Cr
Satisfied ₹7.75 Cr
About Norris Medicines Limited
Data last updated:
Norris Medicines Limited is a public limited company based in Ankleshwar, Gujarat, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 07 September 1990 and has been in existence for over 36 years.
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L24230GJ1990PLC086581. Its GSTIN is 24AAACN1258L1ZI (Gujarat). It is a listed company as per MCA records. Its shares are listed on BSE: 524414.
The company has an authorised share capital of ₹10.1 Cr and a paid-up capital of ₹9.93 Cr. It is led by directors including Vimal Dhirendra Shah and Praveenchand Bafna.
Its last annual general meeting (AGM) was held on 29 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Plot No. 801/P GIDC, Ankleshwar, Gujarat, India – 393002.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹8.13 Cr, a growth of 39.7% compared to the previous year. For the same year it recorded a net loss of ₹28 Lakh (net margin -3.4%) and EBITDA of ₹66 Lakh (EBITDA margin 8.1%). Total assets are valued at ₹6.39 Cr (down 4.8% YoY).
The company has about 15 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Norris Medicines. As per MCA filings, the company has open charges of ₹3.57 Cr and satisfied charges of ₹7.75 Cr on record. Court records list 39 cases involving the company, including 10 filed by the company and 29 filed against it; 11 cases are pending.
Norris Medicines Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-GJ-06-0000911). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website norrispharma.com.
Company details
CIN L24230GJ1990PLC086581
Registration Number 086581
Incorporation Date 07 September 1990
ROC Ahmedabad
Listing Status Listed - Listed on BSE (524414)
Company Status Active
Compliance Status Active Compliant
MSME Classification Small
Udyam Registration UDYAM-GJ-06-0000911
CIN history
Norris Medicines has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24230GJ1990PLC086581, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24230GJ1990PLC086581 | Current |
| L24230MH1990PLC058071 | Previous |
| U24230MH1990PLC058071 | Previous |
Recognitions & Rankings of Norris Medicines
Contact details
Norris Medicines Limited's registered office is in Ankleshwar, Gujarat. Its website is norrispharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressPlot No. 801/P GIDC, Ankleshwar, Gujarat, India – 393002
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Norris Medicines Limited, buy the company report.
Comprehensive company report
Norris Medicines Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Norris Medicines operates one associated brand: Norris Medicines. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Non-sterile and sterile dosage formulations are manufactured and exported. | norrispharma.com |
Business activity
The main business activity of Norris Medicines is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Norris Medicines Limited, buy the company report.
Financials of Norris Medicines Limited
FY 2025-26 filings availableNorris Medicines Limited reported revenue of ₹8.13 Cr (up 39.7% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue
₹8.13 Cr
+39.7% YoY
EBITDA
₹0.66 Cr
+353.8% YoY
Profit After Tax
−₹0.28 Cr
+77.4% YoY
Net Worth
−₹15.14 Cr
-1.9% YoY
Total Assets
₹6.39 Cr
-4.8% YoY
Total Debt
₹21.53 Cr
-0.2% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 8.13 | 5.82 | 5.64 | 8.36 | 9.44 | 12.25 | 7.84 |
| Revenue growth | +39.7% | +3.2% | -32.5% | -11.4% | -22.9% | +56.3% | - |
| EBITDA | 0.66 | (0.26) | (0.17) | 0.93 | (0.07) | (1.74) | (2.16) |
| EBITDA margin | +8.1% | -4.5% | -3.0% | +11.1% | -0.7% | -14.2% | -27.6% |
| Profit before tax | (0.28) | (1.18) | (1.08) | (1.19) | (2.18) | (3.99) | (3.68) |
| Net profit | (0.28) | (1.24) | (1.15) | (1.75) | (3.26) | (4.96) | (2.84) |
| Net profit margin | -3.4% | -21.3% | -20.4% | -20.9% | -34.5% | -40.5% | -36.2% |
| EPS (₹) | (0.28) | (1.25) | (1.20) | (1.76) | (3.29) | (5.00) | (2.86) |
| Balance sheet | |||||||
| Total assets | 6.39 | 6.71 | 7.89 | 8.96 | 10.38 | 8.09 | 15.45 |
| Net worth | (15.14) | (14.86) | (13.63) | (12.44) | (10.69) | (7.43) | (2.46) |
| Total debt | 21.53 | 21.58 | 21.52 | 21.40 | 21.08 | 15.52 | 17.92 |
| Cash & bank | 0.02 | 0.04 | 0.04 | 0.02 | 0.02 | 0.02 | 0.06 |
| Net working capital | (0.69) | (0.75) | (0.15) | 0.20 | 0.46 | (3.46) | 2.33 |
| Cash flow | |||||||
| Cash from operations | 0.59 | 0.51 | 0.17 | 1.20 | (1.01) | 1.11 | (2.88) |
| Cash from investing | (0.09) | 0.00 | 0.05 | (0.02) | (0.09) | (0.06) | 0.00 |
| Cash from financing | (0.52) | (0.50) | (0.20) | (1.18) | 1.10 | (1.09) | 2.86 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.92 | 1.41 | 3.27 | 2.00 | 1.46 | 2.72 | 1.11 | 1.27 |
| Revenue growth (YoY) | -37.0% | -48.2% | +194.6% | +57.5% | +102.8% | - | - | - |
| Other income | 0.00 | 0.02 | 0.00 | 0.00 | 0.02 | 0.05 | 0.00 | 0.00 |
| Total expenses | 1.21 | 1.10 | 2.32 | 2.49 | 1.56 | 2.65 | 1.13 | 1.41 |
| EBITDA | (0.29) | 0.31 | 0.95 | (0.49) | (0.10) | 0.07 | (0.02) | (0.14) |
| EBITDA margin | -31.5% | +22.0% | +29.1% | -24.5% | -6.8% | +2.6% | -1.8% | -11.0% |
| Depreciation | 0.11 | 0.12 | 0.12 | 0.12 | 0.12 | 0.14 | 0.13 | 0.13 |
| Interest | 0.00 | 0.15 | 0.13 | 0.11 | 0.11 | 0.15 | 0.12 | 0.08 |
| Profit before tax | (0.40) | 0.06 | 0.70 | (0.72) | (0.31) | (0.17) | (0.27) | (0.35) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 0.00 | 0.00 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 13 Nov 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.92 | 1.41 | 3.27 | 2.00 | 1.46 | 2.72 | 1.11 | 1.27 |
| Revenue growth (YoY) | -37.0% | -48.2% | +194.6% | +57.5% | +102.8% | - | - | - |
| Other income | 0.00 | 0.02 | 0.00 | 0.00 | 0.02 | 0.05 | 0.00 | 0.00 |
| Total expenses | 1.21 | 1.10 | 2.32 | 2.49 | 1.56 | 2.65 | 1.13 | 1.41 |
| EBITDA | (0.29) | 0.31 | 0.95 | (0.49) | (0.10) | 0.07 | (0.02) | (0.14) |
| EBITDA margin | -31.5% | +22.0% | +29.1% | -24.5% | -6.8% | +2.6% | -1.8% | -11.0% |
| Depreciation | 0.11 | 0.12 | 0.12 | 0.12 | 0.12 | 0.14 | 0.13 | 0.13 |
| Interest | 0.00 | 0.15 | 0.13 | 0.11 | 0.11 | 0.15 | 0.12 | 0.08 |
| Profit before tax | (0.40) | 0.06 | 0.70 | (0.72) | (0.31) | (0.17) | (0.27) | (0.35) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 0.00 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 8.13 | 5.82 | 5.64 | 8.36 | 9.44 | 12.25 | 7.84 |
| Revenue growth | +39.7% | +3.2% | -32.5% | -11.4% | -22.9% | +56.3% | - |
| Other income | 0.05 | 0.06 | 0.03 | 0.01 | 0.03 | 0.05 | 0.09 |
| Total expenses | 7.47 | 6.08 | 5.81 | 7.43 | 9.51 | 13.99 | 10.00 |
| Employee cost | 0.00 | 1.41 | 1.82 | 2.30 | 2.33 | 3.10 | 3.23 |
| EBITDA | 0.66 | (0.26) | (0.17) | 0.93 | (0.07) | (1.74) | (2.16) |
| EBITDA margin | +8.1% | -4.5% | -3.0% | +11.1% | -0.7% | -14.2% | -27.6% |
| Depreciation | 0.49 | 0.54 | 0.57 | 0.63 | 0.66 | 0.67 | 0.73 |
| Interest | 0.50 | 0.44 | 0.37 | 1.50 | 1.48 | 1.63 | 0.88 |
| Profit before tax | (0.28) | (1.18) | (1.08) | (1.19) | (2.18) | (3.99) | (3.68) |
| Tax | 0.00 | 0.06 | 0.09 | 0.56 | 1.08 | 0.97 | (0.84) |
| Net profit | (0.28) | (1.24) | (1.15) | (1.75) | (3.26) | (4.96) | (2.84) |
| Net profit margin | -3.4% | -21.3% | -20.4% | -20.9% | -34.5% | -40.5% | -36.2% |
| EPS (₹) | (0.28) | (1.25) | (1.20) | (1.76) | (3.29) | (5.00) | (2.86) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 |
| Reserves & surplus | (25.07) | (24.79) | (23.56) | (22.37) | (20.62) | (17.36) | (12.39) |
| Shareholders' funds (net worth) | (15.14) | (14.86) | (13.63) | (12.44) | (10.69) | (7.43) | (2.46) |
| Secured loans | 3.02 | 3.05 | 2.99 | 3.24 | 3.42 | 0.57 | 2.94 |
| Unsecured loans | 18.51 | 18.53 | 18.53 | 18.16 | 17.66 | 14.95 | 14.98 |
| Total debt | 21.53 | 21.58 | 21.52 | 21.40 | 21.08 | 15.52 | 17.92 |
| Total liabilities | 6.39 | 6.71 | 7.89 | 8.96 | 10.38 | 8.09 | 15.45 |
| Assets | |||||||
| Gross block | 27.77 | 27.76 | 27.74 | 27.95 | 27.92 | 27.87 | 27.78 |
| Net block | 4.79 | 5.27 | 5.78 | 6.47 | 7.07 | 7.67 | 8.25 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Inventories | 3.98 | 4.13 | 4.33 | 3.20 | 2.42 | 5.10 | 4.01 |
| Sundry debtors | 1.17 | 1.41 | 1.06 | 1.10 | 1.09 | 1.79 | 2.76 |
| Cash & bank balances | 0.02 | 0.04 | 0.04 | 0.02 | 0.02 | 0.02 | 0.06 |
| Loans & advances | 0.64 | 0.77 | 0.71 | 0.60 | 0.74 | 1.32 | 0.61 |
| Total current assets | 5.81 | 6.35 | 6.14 | 4.92 | 4.27 | 8.23 | 7.44 |
| Total current liabilities | 6.50 | 7.10 | 6.29 | 4.72 | 3.81 | 11.69 | 5.11 |
| Net working capital | (0.69) | (0.75) | (0.15) | 0.20 | 0.46 | (3.46) | 2.33 |
| Total assets | 6.39 | 6.71 | 7.89 | 8.96 | 10.38 | 8.09 | 15.45 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.04 | 0.04 | 0.02 | 0.02 | 0.02 | 0.06 | 0.08 |
| Net cash from operating activities | 0.59 | 0.51 | 0.17 | 1.20 | (1.01) | 1.11 | (2.88) |
| Net cash from investing activities | (0.09) | 0.00 | 0.05 | (0.02) | (0.09) | (0.06) | 0.00 |
| Net cash from financing activities | (0.52) | (0.50) | (0.20) | (1.18) | 1.10 | (1.09) | 2.86 |
| Net change in cash | (0.02) | 0.00 | 0.02 | 0.00 | 0.00 | (0.04) | (0.02) |
| Closing cash | 0.02 | 0.04 | 0.04 | 0.02 | 0.02 | 0.02 | 0.06 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +39.7% | +3.2% | -32.5% | -11.4% | -22.9% | +56.3% | - |
| EBITDA growth | +353.9% | -52.9% | -118.3% | +1428.6% | +96.0% | +19.4% | - |
| PBT growth | +76.3% | -9.3% | +9.2% | +45.4% | +45.4% | -8.4% | -81.3% |
| Net income growth | +77.4% | -7.8% | +34.3% | +46.3% | +34.3% | -74.7% | - |
| Revenue CAGR (3Y) | -0.9% | -14.9% | -22.8% | +2.2% | -16.6% | -3.4% | -27.4% |
| EBITDA CAGR (3Y) | -10.8% | +54.9% | -53.9% | - | -51.9% | -3.1% | +200.0% |
| Profitability & leverage | |||||||
| Net income margin | -3.4% | -21.3% | -20.7% | -20.9% | -34.5% | -40.5% | -36.2% |
| Return on capital employed | - | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Return on net worth | - | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Debt / equity | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-term debt / equity | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 294.12 | -55.00 | -50.00 | 500.00 | -202.74 | -67.63 | -30.45 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 0.21 | 0.20 | 0.30 | 0.34 | 0.44 | 0.28 |
| Inventory turnover | - | 1.38 | 1.50 | 2.98 | 2.51 | 2.69 | 2.03 |
| Debtors turnover | - | 4.71 | 5.22 | 7.63 | 6.56 | 5.38 | 2.74 |
| EPS (₹) | (0.28) | (1.25) | (1.20) | (1.76) | (3.29) | (5.00) | (2.86) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | (14.98) | (13.73) | (12.54) | (10.77) | (7.49) | (2.49) |
To see the full year-wise statements and ratios of Norris Medicines Limited, buy the company report.
Board of directors of Norris Medicines Limited
Norris Medicines has 3 current directors and 14 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Vimal Dhirendra Shah Also directs: Kruger Metal Melter Private Limited, Fab Metals Private Limited | Director | 29 Dec 2023 | 2 Years 10 Months | Current |
| Praveenchand Bafna | Director | 24 Aug 2024 | 2 Years 2 Months | Current |
| Angamuthu Vadivel | Director | 29 Apr 2024 | 2 Years 6 Months | Current |
Peer comparison
Norris Medicines Limited is compared with the 3 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Norris Medicines Limitedthis company | ₹8.13 Cr (FY 2026) | -₹28 Lakh | -3.4% | 39.7% | 15 | Ankleshwar, Gujarat, India |
| Sai Teja Drugs and Intermidiates Private Limited | ₹5.89 Cr (FY 2025) | 70.0% | Hyderabad, Telangana, India | |||
| Adman Formulation Pvt Ltd | ₹5.89 Cr (FY 2025) | -9.0% | Indore, Madhya Pradesh, India | |||
| Coastal Medicare Private Limited | ₹5.86 Cr (FY 2024) | 1.0% | Hyderabad, Telangana, India |
To see the full peer comparison of Norris Medicines Limited, buy the company report.
Auditor
Norris Medicines Limited is audited by BAHEDIA & ASSOCIATES for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| BAHEDIA & ASSOCIATES | FY 2024 | 114421W |
Shareholding
Shareholding for the quarter ended Mar 2026: promoters hold 34.00%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.10% and retail and other public shareholders hold 65.90%.
Mar 2026
QUARTER
34.00% Promoters
0.10% DII (Domestic Institutional)
65.90% Retail & Others
Promoter holding - history
Now 34.00% · Mar 2026High 34.00% · Jun 2025Low 34.00% · Jun 2025
Shareholding trend - last 6 quarters
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | |
|---|---|---|---|---|
| Promoters | 34.00% | 34.00% | 34.00% | 34.00% |
| Public | 66.00% | 66.00% | 66.00% | 66.00% |
Charges & borrowings
Open charges
₹3.57 Cr
Satisfied charges
₹7.75 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 27 Jun 2014 | 10510391 | City Union Bank Limited | ₹3.57 Cr | Open | |
| 01 Nov 1995 | 80026576 | Dena Bank | ₹7.75 Cr | Satisfied |
To see the full charge records of Norris Medicines Limited, buy the company report.
Total charge records: 2 View all charges
Legal cases
Norris Medicines Limited has 39 court cases on record: 10 filed by Norris Medicines, 29 filed against it. 11 cases are pending and 28 are disposed.
Total cases
39
Filed by the company
10
Filed against the company
29
Pending
11
Disposed
28
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 29 | 24 | 9 |
| High courts | 8 | 4 | 2 |
| Supreme Court | 2 | 1 | 0 |
Cases on record (5 of 39)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court, GUJARAT | Court case (CIA) | Filed against the company by Franco Indian Remedies Private Limited | Pending |
| District court, Bharuch, Gujarat | Civil suit | Filed against the company by Remeris Pharma Private Limited Through Its Director Mr Dhaval Barot | Pending |
| District court, Ahmedabad, Gujarat | Court case (SMST R) | Filed against the company by Rachna Air Components Private Limited Through Nimeshbhai Hasmukhbhai Trivedi (Authorized Person) | Disposed |
| District court, Ahmedabad, Gujarat | Court case (CS CCC) | Filed against the company by Torrent Pharmaceuticals Ltd | Disposed |
| District court, Bharuch, Gujarat | Court case (REFER-T-LC) | Filed against the company by an individual | Pending |
To see the full case history of Norris Medicines Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Norris Medicines Limited has 8 MSME Form 1 returns on record between 2019 and 2024, listing 82 overdue payments to 19 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 19)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| Mayur Thakkar & Co. | |||
| Rajrappa Packaging | |||
| Precitech Laboratories Private Limited | |||
| an individual supplier |
To see the full MSME payment records of Norris Medicines Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Norris Medicines Limited has a workforce of 15 employees on its EPFO records as of Aug 2025, across 1 active EPFO establishment.
Employee count
15
Active EPFO establishments
1
Employee growth
-28.6%
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2025-26 | 15 |
| FY 2024-25 | |
| FY 2023-24 | |
| FY 2022-23 | |
| FY 2021-22 | |
| FY 2020-21 | |
| FY 2019-20 | |
| FY 2018-19 | |
| FY 2017-18 | |
| FY 2016-17 |
To see the full employee and EPFO history of Norris Medicines Limited, buy the company report.
GST
Norris Medicines has 1 GST registration: 1 active.
Total GSTINs
1
Active
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AAACN1258L1ZI | Gujarat | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Norris Medicines Limited, buy the company report.
Recent activity
Norris Medicines Limited has 24 board changes on record since 1990: 14 appointments and 10 cessations. The latest: Venkatachalam Sathya was appointed as Director on 25 Sep 2024.
Filing
Norris Medicines Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
AGM
Norris Medicines Limited last Annual general meeting of members was held on 29 Sep 2025 as per latest MCA records.
Appointed
Venkatachalam Sathya was appointed as Director.
Appointed
Praveenchand Bafna was appointed as Director.
Ceased
Shaik Amanullah Mohamed Azmathullah ceased to be Director.
Ceased
Mahapatra Susmita ceased to be Director.
Appointed
Angamuthu Vadivel was appointed as Director.
Ceased
Hiten Mukundbhai Parikh ceased to be Director.
Appointed
Vimal Dhirendra Shah was appointed as Director.
Ceased
Sanjiv Kumar Shah ceased to be Director.
Appointed
Mahapatra Susmita was appointed as Director.
Charges
A charge with City Union Bank Limited of Rs. 3.57 Cr registered on 27 Jun 2014 with Charge ID 10510391 was modified on 18 Jun 2020.
20 earlier events are in the company report.
News
Frequently asked questions
Norris Medicines is an active public limited company based in Ankleshwar, Gujarat, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 07 September 1990 (36+ years old) and is registered under CIN L24230GJ1990PLC086581. Listed on BSE: 524414.
Norris Medicines reported revenue of ₹8.13 Cr for FY 2025-26 (up 39.7% YoY) based on standalone financials.
Norris Medicines has 3 current directors:
- Vimal Dhirendra Shah - Director
- Praveenchand Bafna - Director
- Angamuthu Vadivel - Director
The latest financial statements of Norris Medicines on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 29 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Norris Medicines is 24AAACN1258L1ZI, registered in Gujarat.
The CIN (Corporate Identification Number) of Norris Medicines is L24230GJ1990PLC086581. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Norris Medicines is a listed company as per MCA records. Its shares are listed on BSE (code: 524414).
Norris Medicines has 39 court cases on record: 10 filed by the company and 29 filed against it. 11 are pending. Most are in the district courts.
Norris Medicines was incorporated on 07 September 1990, making it 36+ years old. It is registered with the Registrar of Companies, Ahmedabad.
The peers of Norris Medicines by revenue are Sai Teja Drugs and Intermidiates Private Limited, Adman Formulation Pvt Ltd, Coastal Medicare Private Limited, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Venkatachalam Sathya was appointed as Director on 25 Sep 2024. Praveenchand Bafna was appointed as Director on 24 Aug 2024. Shaik Amanullah Mohamed Azmathullah ceased to be Director on 09 Aug 2024. Norris Medicines has 24 board changes on record in total.
Yes, Norris Medicines is registered as a small enterprise under Udyam registration (number: UDYAM-GJ-06-0000911).
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages